Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis

Journal of Experimental Medicine

Volumn 196, Issue 11, 2002, Pages 1461-1471

  Grant, Ethan P ^a   Picarella, Dominic ^a   Burwell, Timothy ^a   Delaney, Tracy ^a   Croci, Alisa ^a   Avitahl, Nicole ^a   Humbles, Alison A ^b   Gutierrez Ramos, Jose Carlos ^a   Briskin, Michael ^a   Gerard, Craig ^b   Coyle, Anthony J ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Arthritis; C5a receptors; Chemoattractants; Granulocytes; Monocytes

Indexed keywords

ANAPHYLATOXIN; CHEMOATTRACTANT; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; FORMYLMETHIONYLLEUCYLPHENYLALANINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; GENE DELETION; HUMAN; HUMAN CELL; HUMAN TISSUE; JOINT DESTRUCTION; MACROPHAGE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SYNOVIAL FLUID; SYNOVIUM;

ANIMALS; ANTIGENS, CD; ARTHRITIS; COLLAGEN; COMPLEMENT ACTIVATION; COMPLEMENT C5; E-SELECTIN; GENE EXPRESSION; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; JOINTS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEUTROPHILS; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, COMPLEMENT; RECEPTORS, COMPLEMENT 3B; SYNOVIAL MEMBRANE; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0037011022     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20020205     Document Type: Article

References (34)

1. Firestein, G.S. 1996. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum. 39:1781-1790.
2. Kinne, R.W., R. Brauer, B. Stuhlmuller, E. Palombo-Kinne, and G.R. Burmester. 2000. Macrophages in rheumatoid arthritis. Arthritis Res. 2:189-202.
3. Choy, E.H., and G.S. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344:907-916.
4. Fox, D.A. 1997. The role of T cells in the immunopathogenesis of rheumatoid arthritis: New perspectives. Arthritis Rheum. 40:598-609.
5. Plater-Zyberk, C., A.J. Hoogewerf, A.E. Proudfoot, C.A. Power, and T.N. Wells. 1997. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol. Lett. 57:117-120.
6. Gong, J.H., L.G. Ratkay, J.D. Waterfield, and I. ClarkLewis. 1997. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J. Exp. Med. 186:131-137.
7. Ogata, H., M. Takeya, T. Yoshimura, K. Takagi, and K. Takahashi. 1997. The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J. Pathol. 182:106-114.
8. Gerard, C., and N.P. Gerard. 1994. The pro-inflammatory seven-transmembrane segment receptors of the leukocyte. Curr. Opin. Immunol. 6:140-145.
9. Feldmann, M., F.M. Brennan, and R.N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14: 397-440.
10. Gerard, C., and B.J. Rollins. 2001. Chemokines and disease. Nat. Immunol. 2:108-115.
11. Pope, R.M., and H. Perlman. 2000. Rheumatoid arthritis. In Principles of Molecular Rheumatology. G.C. Tsokos, editor. Humana Press, Totowa, NJ. 325-361.
12. Stuart, J.M., and F.J. Dixon. 1983. Serum transfer of collagen-induced arthritis in mice. J. Exp. Med. 158:378-392.
13. Kouskoff, V., A.S. Korganow, V. Duchatelle, C. Degott, C. Benoist, and D. Mathis. 1996. Organ-specific disease provoked by systemic autoimmunity. Cell. 87:811-822.
14. Gerard, C., and N.P. Gerard. 1994. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu. Rev. Immunol. 12:775-808.
15. Wetsel, R.A., J. Kildsgaard, and D.L. Haviland. 2000. Complement anaphylatoxins (C3a, C4a, C5a) and their receptors (C3aR, C5aR/CD88) as therapeutic targets in inflammation. In Therapeutic Interventions in the Complement System. J.D. Lambris and V.M. Holers, editors. Humana Press, Totowa, NJ. 113-153.
16. Humbles, A.A., B. Lu, C.A. Nilsson, C. Lilly, E. Israel, Y. Fujiwara, N.P. Gerard, and C. Gerard. 2000. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature. 406:998-1001.
17. Bautsch, W., H.G. Hoymann, Q. Zhang, I. Meier-Wiedenbach, U. Raschke, R.S. Ames, B. Sohns, N. Flemme, A. Meyer zu Vilsendorf, M. Grove, et al. 2000. Cutting edge: Guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: Evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma. J. Immunol. 165:5401-5405.
18. Hopken, U.E., B. Lu, N.P. Gerard, and C. Gerard. 1996. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature. 383:86-89.
19. Moxley, G., and S. Ruddy. 1985. Elevated C3 anaphylatoxin levels in synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum. 28: 1089-1095.
20. Moxley, G., and S. Ruddy. 1987. Elevated plasma C3 anaphylatoxin levels in rheumatoid arthritis patients. Arthritis Rheum. 30:1097-1104.
21. Jose, P.J., I.K. Moss, R.N. Maini, and T.J. Williams. 1990. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: Role of C5a in the acute inflammatory phase. Ann. Rheum. Dis. 49: 747-752.
22. Hamann, J., J.O. Wishaupt, R.A. van Lier, T.J. Smeets, F.C. Breedveld, and P.P. Tak. 1999. Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis Rheum. 42:650-658.
23. Korganow, A.S., H. Ji, S. Mangialaio, V. Duchatelle, R. Pelanda, T. Martin, C. Degott, H. Kikutani, K. Rajewsky, J.L. Pasquali, et al. 1999. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 10:451-461.
24. Wang, Y., J. Kristan, L. Hao, C.S. Lenkoski, Y. Shen, and L.A. Matis. 2000. A role for complement in antibody-mediated inflammation: C5-deficient DBA/1 mice are resistant to collagen-induced arthritis. J. Immunol. 164:4340-4347.
25. Ji, H., K. Ohmura, U. Mahmood, D.M. Lee, F.M. Hofhuis, S.A. Boackle, K. Takahashi, V.M. Holers, M. Walport, C. Gerard, et al. 2002. Arthritis critically dependent on innate immune system players. Immunity. 16:157-168.
26. Daffern, P.J., P.H. Pfeifer, J.A. Ember, and T.E. Hugli. 1995. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J. Exp. Med. 181:2119-2127.
27. Martin, U., D. Bock, L. Arseniev, M.A. Tornetta, R.S. Ames, W. Bautsch, J. Kohl, A. Ganser, and A. Klos. 1997. The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. J. Exp. Med. 186:199-207.
28. Zwirner, J., O. Gotze, G. Begemann, A. Kapp, K. Kirchhoff, and T. Werfel. 1999. Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. Immunology. 97:166-172.
29. Wipke, B.T., and P.M. Allen. 2001. Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J. Immunol. 167:1601-1608.
30. Kong, Y.Y., H. Yoshida, I. Sarosi, H.L. Tan, E. Timms, C. Capparelli, S. Morony, AJ. Oliveira-dos-Santos, G. Van, A. Itie, et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 397:315-323.
31. Kong, Y.Y., U. Feige, I. Sarosi, B. Bolon, A. Tafuri, S. Morony, C. Capparelli, J. Li, R. Elliott, S. McCabe, et al. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 402:304-309.
32. Johansson, A.C., M. Sundler, P. Kjellen, M. Johannesson, A. Cook, A.K. Lindqvist, B. Nakken, A.I. Bolstad, R. Jonsson, M. Alarcon-Riquelme, et al. 2001. Genetic control of collagen-induced arthritis in a cross with NOD and C57BL/10 mice is dependent on gene regions encoding complement factor 5 and FcgammaRIIb and is not associated with loci controlling diabetes. Eur. J. Immunol. 31:1847-1856.
33. Ji, H., D. Gauguier, K. Ohmura, A. Gonzalez, V. Duchatelle, P. Danoy, H.J. Garchon, C. Degott, M. Lathrop, C. Benoist, et al. 2001. Genetic influences on the end-stage effector phase of arthritis. J. Exp. Med. 194:321-330.
34. Wang, Y., S.A. Rollins, J.A. Madri, and L.A. Matis. 1995. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA. 92:8955-8959.